The DOI matches its Crossref record; 170 of the 175 references it cites were found in a registry or an index.
Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies
Abstract
Multiple lines of evidence including recent imaging studies suggest that schizophrenia is associated with an imbalance of the dopaminergic system, entailing hyperstimulation of striatal dopamine (DA) D2 receptors and understimulation of cortical DA D1 receptors. This DA endophenotype presumably emerges from the background of a more general synaptic dysconnectivity, involving alterations in N-methyl-d-aspartate (NMDA) and glutamatergic (GLU) functions. Equally important is the fact that this DA dysregulation might further impair NMDA transmission. The first generation antipsychotic (FGA) drugs are characterized by high affinity to and generally high occupancy of D2 receptors. The efficacy of FGAs is limited by a high incidence of extrapyramidal side-effects (EPS). Second generation antipsychotic (SGA) drugs display reduced EPS liability and modest but clinically significant enhanced therapeutic efficacy. Compared to FGAs, the improved therapeutic action of SGAs probably derives from a more moderate D2 receptor blockade. We will review the effects of SGAs on other neurotransmitter systems and conclude by highlighting the importance of therapeutic strategies aimed at directly increasing prefrontal DA, D1 receptor transmission or NMDA transmission to enhance the therapeutic effect of moderate D2 receptor antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is also consistent with the currently available pharmacological treatments, whose neurobiological mechanism is thought to rely on restoring dopamine to physiological levels (Abi-Dargham and Laruelle, 2005; Gerlach et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Abi-Dargham and Laruelle, 2005
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
From motivation to action: Functional interface between the limbic system and the motor system
MOGENSON, G., JONES, D., & YIM, C. (1980) · Progress in Neurobiology · doi:10.1016/0301-0082(80)90018-0 · Cited by 2,331
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,156
Dopamine in schizophrenia: a review and reconceptualization
Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,051
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Flagged first, then by citations
5 of the 175 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Lindvall, 1983, Chemical neuroanatom, 229
- Kolachana, 1996, Abnormal prefrontal cortical regulation of striatal dopamine release after neonatal medial temporal-limbic lesions in rhesus monkeys, Soc Neurosci
- Weinberger, 2001, Neuropharmacology—the fifth generation of progres
Cited by
Sorted by citations
Items 101–179 of 179
Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
Tuppurainen, H., Kuikka, J. T., Viinamäki, H. T., Husso, M., & Tiihonen, J. (2010) · Nordic Journal of Psychiatry · doi:10.3109/08039480903484076 · Cited by 12
Gao, M., Liu, C., Shen, Y. A. N. G., Xue-chu, Z. H. E. N., & Jin, G.-Z. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00547.x · Cited by 12
Schneider, S., Bahmer, T. J., Metzger, F. G., Reif, A., Polak, T. T., Pfuhlmann, B., Walter, G., Eberle, M.-C., Ernst, L. H., Fallgatter, A. J., et al. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000540 · Cited by 11
How have developments in molecular imaging techniques furthered schizophrenia research?
Thompson, J. L., Urban, N., & Abi‐Dargham, A. (2009) · Imaging in Medicine · doi:10.2217/iim.09.22 · Cited by 9
Self-citationKjelby, E., Gjestad, R., Fathian, F., Sinkeviciute, I., Alisauskiene, R., Anda, L. G., Løberg, E., Reitan, S. K., Joa, I., Larsen, T. K., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001679 · Cited by 10
Assié, M., Bardin, L., Auclair, A. L., Consul-Denjean, N., Sautel, F., Depoortère, R., & Newman‐Tancredi, A. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0162-x · Cited by 10
Effect of sepsis on behavioral changes on the ketamine-induced animal model of schizophrenia
Comim, C. M., Silva, N. C., Patrício, J. J. S., Palmas, D., Mendonça, B. P., Bittencourt, M. O., Cassol-Jr, O. J., Barichello, T., Zugno, A. I., Quevedo, J., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.02.012 · Cited by 9
Natchimuthu, V., Abdalla, M., Yadav, M., Chopra, I., Bhrdwaj, A., Sharma, K., Ravi, S., Ravikumar, K., Alzahrani, K. J., Hussain, T., et al. (2022) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2022.2063278 · Cited by 9
Le récepteur dopaminergique D3: nouvelle cible pour un traitement amélioré de la schizophrénie
Millan, M. J. (2005) · médecine/sciences · doi:10.1051/medsci/2005214434 · Cited by 9
Mamrack, M. D. (2020) · Routledge eBooks · doi:10.4324/9781003035381-12 · Cited by 9
Regulation of GSK-3 Activity as A Shared Mechanism in Psychiatric Disorders
Şahin, C., Ünal, G., & Arıcıoğlu, F. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20140317063255 · Cited by 9
Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics
Zergiebel, S., Fleck, C., Arndt, H., Enzensperger, C., & Seeling, A. (2017) · Drug Research · doi:10.1055/s-0043-108651 · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Iloperidone: a new option for the treatment of schizophrenia
Cutler, A. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.119 · Cited by 7
Applications of Clinical Dopamine Imaging
Lindsey, K. P., & Gatley, S. J. (2006) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2006.06.003 · Cited by 7
Johnsen, E., Fasmer, O. B., van Wageningen, H., Hugdahl, K., Hauge, E. R., & Jørgensen, H. A. (2012) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2012.00674.x · Cited by 6
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents
Etiévant, A., Betry, C., & Haddjeri, N. (2010) · The Open Neuropsychopharmacology Journal · Cited by 6
Serafine, K. M., & France, C. P. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000015 · Cited by 6
Free, R. B., Nilson, A. N., Boldizsar, N. M., Doyle, T. B., Rodriguiz, R. M., Pogorelov, V. M., Machino, M., Lee, K. H., Bertz, J. W., Xu, J., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00202 · Cited by 5
A Systematic Review of Oral Vertical Dyskinesia (“Rabbit” Syndrome)
Rissardo, J. P., Kherajani, K., Vora, N. M., Yatakarla, V., Caprara, A. L. F., Ratliff, J. B., & Caroff, S. N. (2024) · Medicina · doi:10.3390/medicina60081347 · Cited by 5
Chawla, N., Mandal, P., Chatterjee, B., & Dhawan, A. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12789 · Cited by 5
Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies
Kristiansen, L. V., Cowell, R. M., Biscaia, M., McCullumsmith, R. E., & Meador‐Woodruff, J. H. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_14 · Cited by 5
Pharmacotherapy of Schizophrenia
Sharif, Z. A., Miyamoto, S., & Lieberman, J. A. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn033 · Cited by 5
Pavan, B., Paganetto, G., & Dalpiaz, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.03.010 · Cited by 4
Long‐term effects of iloperidone on cerebral dopamine receptor subtypes
Choi, Y. K., & Tarazi, F. I. (2018) · Synapse · doi:10.1002/syn.22039 · Cited by 4
Tufvesson‐Alm, M., Walsh, L., Pierce, S., Keohane, F., Clarke, G. A., O’Connor, K. M., Cryan, J. F., & Schellekens, H. (2026) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2026.2637716 · Cited by 4
Imagerie cérébrale et schizophrénie
Barbalat, G., & Franck, N. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)59579-9 · Cited by 3
2.2 Functional Implications of Dopamine D2 Receptor Localization in Relation to Glutamate Neurons
Sesack, S. R. (2009) · doi:10.1093/acprof:oso/9780195373035.003.0003 · Cited by 3
Cariprazine: Pharmacology and Use in the Clinical Management of Psychiatric Disorders
Reyad, A. A., & Mishriky, R. S. L. (2019) · Psychiatric Annals · doi:10.3928/00485713-20190213-01 · Cited by 3
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50043-8 · Cited by 3
Dopamine and Glutamate Hypotheses of Schizophrenia
Moghaddam, B., & Homayoun, H. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn030 · Cited by 3
Novel Approaches for the Treatment of Schizophrenia
Rogers, B. N., & Schmidt, C. J. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41001-0 · Cited by 3
Zhang, J., Deng, X., Lv, J., Lu, J., Wang, L., Wang, W., Lei, H., Wang, Y., & Tian, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1759454 · Cited by 2
Applications of Clinical Dopamine Imaging
Lindsey, K. P., & Gatley, S. J. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.09.005 · Cited by 2
Aetiology and Risk Factors of Schizophrenia
Kuşman, A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005178 · Cited by 2
Adipocyte Triglyceride Content and Adipogenesis in Aripiprazole Treated Rats
Gáll, Z., Vancea, S., Mezei, T., & Kolcsár, M. (2013) · International Journal of Pharmacology · doi:10.3923/ijp.2013.251.257 · Cited by 2
Chapter 6.1 The role of microdialysis in drug discovery: focus on antipsychotic agents
Millan, M. J., Panayi, F., Rivet, J., Cara, B. D., Cistarelli, L., Billiras, R., Girardon, S., & Gobert, A. (2006) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(06)16026-9 · Cited by 2
Kokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/748665 · Cited by 2
Use of the Clinical Laboratory in Psychiatric Practice
Aloezos, C., Wai, J. M., Bluth, M. H., & Forman, H. P. (2016) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2016.07.004 · Cited by 1
Azargoonjahromi, A., & Nasiri, H. (2025) · Psychiatric Quarterly · doi:10.1007/s11126-025-10226-7 · Cited by 1
Wang, L., Li, Y., Wang, Y., Liu, J., Han, Y., Wang, L., Sun, W., Wang, L., & Li, S. (2025) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2025.2581683 · Cited by 1
Salem, A., & Moustafa, A. A. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00131 · Cited by 1
Würzburg, J.-M.-U., & Ehlis, A. (2007) · Cited by 1
Pei, J.-C., Chang, C.-Y., Liu, Y., Chen, C., Liu, C.-Y., Hsieh, M. H., Liu, C., & Lai, W. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf070 · Cited by 1
Modeling of schizophrenia with Levodopa+Carbidopa
Kutcher, E. O., Egorov, A. Y., Chernikova, N. A., & Филатова, Е. В. (2013) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s002209301305006x · Cited by 1
Kynurenic acid in psychiatric disorders : studies on the mechanisms of action
Linderholm, K. R. (2010) · Figshare · Cited by 1
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.637
Kjelby, E., Gjestad, R., Fathian, F., Sinkeviciute, I., Alisauskiene, R., Anda, L. G., Løberg, E., Reitan, S. K., Joa, I., Larsen, T. K., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001800 · Cited by 1
Avaliação do potencial efeito antipsicótico da miricitrina em modelos animais
Pereira, M. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Schizophrenia: A review of neuroimaging techniques and findings
Yıldırım, A., & Türeli, D. (2014) · Van Yüzüncü Yıl University Academic Data Management System
Biological treatments for psychotic disorders
Girgis, R. R., Schobel, S., & Lieberman, J. A. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544125.027
Dopamine D2/D3Partial Agonists as Antipsychotics
Strange, P. G. (2012) · doi:10.1002/9781118309421.ch2
Glutamatergic mechanisms in schizophrenia : Role of endogenous kynurenic acid
Nilsson, L. K. (2005) · Figshare
Apport de la neuro-imagerie dans le diagnostic
Barbalat, G., & Nicolas Franck, B. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0505-4_4
Adaptations neuronales dans les maladies psychiatriques associées à une hyperdopaminergie
Rawas, R. E. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Dopamine regulation in schizotypal personality disorder and psychosis
Chemerinski, E., Siever, L. J., & Koenigsberg, H. W. (2005) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629449
Jafari, S. (2012) · Research Online (University of Wollongong)
Dash, R., & Ramanathan, K. (2013)
Atalar, F., Acuner, T. T., Çine, N., Öncü, F., Yeşilbursa, D., Özbek, U., & Türkcan, S. (2010)
Basic Foundations of Diagnosis, Psychiatric Diagnosis, and Final Common Pathway Syndromes
Leigh, H. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_7
Bateup, H. S. (2025) · Digital Commons - RU (Rockefeller University) · doi:10.48496/p78x-kb92
Khalil, H. (2016) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.17113
Molecular imaging of dopamine synthesis and release
Shotbolt, J. (2013) · Spiral (Imperial College London) · doi:10.25560/11152
Quartarone, S. E. (2014) · QSpace (Queen's University Library)
Unmet medical needs in schizophrenia treatments
Shad, M. U. (2012) · doi:10.2217/ebo.11.277
The Effects of Atypical Antipsychotics on Implicit Reward Learning in Schizophrenia
Bradford, L. (2015) · QSpace (Queen's University Library)
Effects of neuroleptics and antidepressants on the cardiovascular system: literature review
Rutkauskas, V. (2019) · Neurologijos seminarai · doi:10.29014/ns.2019.17
Sistemas dopaminérgicos e ação antipsicótica: abordagens experimentais e teóricas
Tort, A. B. L. (2005) · Americanae (AECID Library)
(2009) · CRC Press eBooks · doi:10.3109/9780203092835-3
Hyperbaric Oxygen Therapy Ameliorates Olanzapine-Induced Hypolocomotion in a Rat Model
Altarifi, A., Arab, L., Al-Azaizeh, R., Khataybeh, B., Al‐Ghadi, M. Q., & Khalifeh, M. (2024) · Life · doi:10.3390/life14111482
Utilizing Intranasal Drug Delivery Systems for Novel Antipsychotics Drug Development
Ainurofiq, A., Priyanto, F. A. P., Suryadi, B. B., & Pamungkas, Y. K. (2024) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.14.4.21 · Cited by 1
Subramaniam, K., Attalla, G., Mathew, M., Alvarez, J. L., Dadgar‐Kiani, E., Mahadevan, R., Nagarajan, S. S., & Murphy, K. R. (2026) · medRxiv · doi:10.64898/2026.01.10.26343837
Madhyastha, S., & Rao, M. S. (2026) · Current Neuropharmacology · doi:10.2174/011570159x409741251202071559
Risk of Parkinson’s disease in patients with schizophrenia: Impact of antipsychotic medication use
Gil, J. Y., Min, K. H., Kim, J. H., Park, J. H., Han, J. M., & Lee, K. E. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346233
Yunxiang, W. A. N. G., Wang, J., Zhang, X., & Liu, X. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1898212
Metadata
- Authors
- Abi-Dargham, A., & Laruelle, M.
- Affiliations
- New York State Psychiatric Institute (US)
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2005-01
- Volume
- 20
- Issue
- 1
- Pages
- 15-27
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2029915913
- Cited by
- 179
- References
- 175
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 17
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08mh001594-05, 5k02mh064178-03)
- National Institute of Mental Health (K02 MH064178-01A2, K02MH01603-01, K02MH001603, K08 MH01594-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- atypical antipsychotics, schizophrenia, dopaminergic system, dopamine D2 receptor antagonism, dopamine D1 receptor, striatal dopamine, NMDA receptor, glutamatergic neurotransmission, extrapyramidal symptoms, typical antipsychotics, prefrontal dopamine, neuroimaging
- MeSH terms
- Brain, Dopamine, Humans, Schizophrenia, Antipsychotic Agents, Tomography, Emission-Computed, Single-Photon, N-Methylaspartate, Receptors, Dopamine D1, Glutamic Acid, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review